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ABSTRACT
A group of 21 consecutive patients aged 4-20 (median 13) years was prospectively allografted using a reduced
intensity preparative regimen. The group included both malignant (acute lymphoblastic leukemia, acute myeloge-
nous leukemia, and chronic myelogenous leukemia) and nonmalignant (aplastic anemia, Diamond-Blackfan anemia,
thalassemia major and adrenoleukodystrophy) conditions. Follow-up times ranged between 16 and 1038 days. Four
of 21 patients (9.5%) developed acute graft-versus-host disease, and 2 of them died, whereas limited chronic
graft-versus-host disease was observed in 2 of 15 cases. The 100-day mortality was 19%. Median overall survival was
above 1038 days, whereas the 34-month survival was 55%. These data show that reduced intensity stem cell
transplantation in children permits rapid engraftment from siblings with little toxicity.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Allogeneic stem cell transplantation is a well-established
treatment for several nonmalignant and malignant diseases in
children. The results of this procedure have improved in recent
years, but such improvement is better explained by the availabil-
ity of highly effective supportive care measures rather than
higher therapeutic effectiveness against the underlying disease.
Despite progress in supportive therapy, myeloablative regimen
toxicity still leads to a high incidence of acute and chronic side
effects and contributes, in combination with the development of
graft-versus-host disease (GVHD), to considerable transplant-
related morbidity and mortality [1-3].
The results of stem cell transplantation in children may [2]
or may not [4] be better than those in adults. The differences
may be due mainly to the lower incidence and severity of organ
toxicity and GVHD in younger patients [2]. On the other hand,
children are more vulnerable to late sequelae, and the condi-
tioning regimen itself accounts for many late effects [2,5].
Therefore the use of less toxic and more effective transplanta-
tion procedures in children should continue to be explored.
Recently, we and others have reported data on reduced
intensity allogeneic stem cell transplantation (RIST) for hema-
tologic disorders, using highly immunosuppressive, nonmyeloa-
blative regimens [6-12]. The majority of these RIST procedures
have been performed in adults, and occasionally in small groups
of children. We report here our experience in 21 children and
adolescents who received allografts with peripheral blood using
a low-intensity conditioning regimen.
MATERIAL AND METHODS
Patients and Donors
All consecutive patients aged 4-20 years were included.
Table 1 shows some of the patients’ characteristics. Those with
hematological malignancies had received prior chemotherapy
and had a Karnofsky score of 80%-100% and those with non-
malignant diseases had a Karnofsky score of 100% when the
procedure was performed. The donor was an HLA-identical
sibling in all instances. Institutional review board approval and
Biology of Blood and Marrow Transplantation 9:157–161 (2003)
 2003 American Society for Blood and Marrow Transplantation
1083-8791/03/0903-0002$30.00/0
doi: 10.1053/bbmt.2003.50004
157BB&MT
written consent from all the patients and/or their parents was
obtained.
Hematopoietic Stem Cell Mobilization and Peripheral
Blood Stem Cell Apheresis
Granulocyte colony-stimulating factor (10 g/kg per day)
was administered to the donors on days4 to1. The apheresis
procedures were performed on days 0 and1; a third procedure
was done when necessary. A Haemonetics V-50 PLUS machine
(Haemonetics Corporation, Braintree, MA) or a Baxter C-3000
PLUS machine (Baxter Health Care, Deerﬁeld, IL) was em-
ployed, following the Spin-Nebraska protocol. The endpoint of
collection was the processing of least 6000-7000 mL of blood
per square meter in each of 3 apheresis procedures [5,6,11], to
obtain at least 1-6 x 108 mononuclear cells per kilogram of the
recipient.
Conditioning and Grafting
A modiﬁcation of the RIST conditioning regimens de-
scribed by Giralt et al. [10] and Slavin et al. [1] was used. In 18
children, 4 mg/kg of oral busulphan was delivered on days 6
and 5; 350 mg/m2 of intravenous cyclophosphamide and 30
mg/m2 was delivered on days 4, 3, and 2; 5 mg/kg of oral
cyclosporin A (CyA) was started on day 1; and 5 mg/m2 of
intravenous methotrexate was delivered on days 1, 3, 5,
and 11. In 2 children with aplastic anemia and 1 with
Diamond-Blackfan anemia, instead of busulphan and cyclophos-
phamide, 70 mg/m2 of intravenous melphalan was given on days
7 and 6, and 30 mg/m2 of intravenous ﬂudarabine was given
on days 6 to 1. Oral CyA was continued through day 100,
with adjustments according to serum CyA; it was then tapered
over 30-60 days. Ondansentron was used in order to avoid
nausea and vomiting, ciproﬂoxacin (250 mg twice daily) and
itraconazole or ﬂuconazole (100 mg twice daily) were used in all
patients; antibiotics and antimycotics were used until more than
0.5 x 109/L granulocytes were present. When either patients or
donors had anticytomegalovirus antibodies, patients were given
oral ganciclovir (250 mg three times daily) for 100 days. The
products of the peripheral blood stem cell apheresis were in-
fused on days 0 and 1, and sometimes 2.
Apheresis Product Studies
Enumeration of the total white blood, mononuclear, and
CD34 cells was done by ﬂow cytometry [13] in an EPICS Elite
ESP apparatus (Coulter Electronics, Hialeah, FL), using the
anti-CD34 monoclonal antibody [14] HPCA-2 (Becton Dickin-
son, San Jose, CA).
Chimerism Studies
In cases with a sex mismatch, a ﬂuorescent in situ hybrid-
ization technique to demonstrate the X and Y chromosomes was
done [15]; in cases with ABO system mismatch a ﬂow cyto-
metry–based approach was used, whereas restriction fragment
length polymorphism studies were used in cases without such
mismatches [16]. Studies were done on days 30 and 60 after the
infusion of the apheresis products.
Table 1. Salient Features of the Allografted Patients
Patient No. Age (y) Sex Diagnosis OP* Status Postallograft Days Chimerism
1 14 M AML-M2 yes D-Rel 323 HLA
2 14 F Thal yes A-Rem 1038 ABO
3 10 M ALL 2 rem yes D-Rel 112 MS
4 4 M ALL 2 rem yes D-Rel 546 HLA
5 17 M ALL 2 rel D-aGVHD 121 ABO
6 12 F ALL 2 rem yes D-Rel 90
7 17 M ALL 2 rel A-Rem† 695 ABO, MS
8 19 M ALL 3 rem A-Rem† 647 ABO
9 20 M ALL 2 rem yes A-Rem 647
10 9 M ALL 2 rem yes D-Rel 277 xx/xy, MS
11 20 M CML A-Rem, cGVHD 491
12 19 F ALL 2 rem D-aGVHD 85
13 12 M ALL 1 rel D-sepsis 16
14 20 M ALL A 149 ABO
15 13 F ALL 2 rel yes A 130 xx/xy, MS
16 5 F DBA yes A-cGVHD 121 xx/xy/Rh/MS/ABO
17 4 M DBA yes A 88
18 12 F AA A 133 ABO
19 9 M ALD yes D-sepsis 50
20 4 M AA A-cGVHD 106 xx/xy
21 9 M ALL ref A 89 xx/xy
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Thal, thalassemia major; AML, acute myelogenous
leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; DBA, Diamond-Blackfan anemia; AA, aplastic anemia; ALD,
adrenoleukodystrophy; A, alive; D, dead; Rel, relapse; Rem, remission; Ref, refractory; HLA, HLA chimerism; ABO, blood group chimerism; MS,
microsatellites chimerism; xx/yy, sex chimerism; Rh, Rh chimerism.
*Outpatient completion of the allograft.
†Patients with aGVHD.
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RESULTS
Twenty-one patients were allografted: 13 with acute lym-
phoblastic leukemia (ALL) (7 in second remission, 1 in third
remission, 1 in ﬁrst relapse, 3 in second relapse, and 1 primarily
refractory to therapy), 1 with acute myelogenous leukemia, 1
with chronic myelogenous leukemia in accelerated phase, 2 with
aplastic anemia, 2 with Diamond-Blackfan anemia, 1 with
thalassemia major, and 1 with adrenoleukodystrophy. The me-
dian age of the patients was 13 years (range 4-20). There were 6
female patients and 15 male patients. The median granulocyte
recovery time to 0.5 x 109/L was 13 days (range 11-34), whereas
the median platelet recovery time to 20 x 109/L was 13 days
(range 11-22). The median number of packed red blood cell
units transfused was 1 (range 0-7) and the median number of
platelet transfusion sessions was 1 (range 0-27). In 11 children
the procedure was completed fully on an outpatient basis.
Follow-up times range between 16 and 1038 days; 15
individuals have been followed up for more than 100 days.
Four of 21 patients (9.5%) developed acute GVHD disease
and 2 of them died, whereas limited chronic GVHD was
observed in 2 of the 15 followed-up cases. The remaining
patients did not develop febrile neutropenia, veno-occlusive
disease, mucositis, severe nausea, or diarrhea. Nine patients
have died, 5 of them as a result of relapse of the malignancy.
In 4 cases toxicity from the procedure was the cause of
death—2 were due to acute GVHD and 2 to overwhelming
infections. The 100-day mortality was 19%. In the whole
group, median overall survival is above 1038 days, whereas
the 34-month survival is 55%. Two-year survival of patients
with nonmalignant diseases was signiﬁcantly higher than that
of children with malignant diseases (83% vs 44%, P.01).
Details of the chimerism kinetics of some of the patients have
been published previously [15]; chimerism with more than
90% in donor cells on day 60 and afterward has been shown
in 13 patients (Table 1). One patient died from sepsis without
any evidence of chimerism (case 13).
The most numerous subgroup consisted of 13 patients
with ALL, 8 in second or third remission, 4 in relapse, and 1
primarily refractory to therapy. Seven of them (53%) died,
with a mean survival time of 178 days. Two of the 4 relapsed
cases are alive and in complete remission at 135 and 700 days
after the RIST, respectively; the patient with refractory ALL
remained alive, 94 days after the graft. The patients with
heavily pretransfused aplastic anemias are alive 106 and 133
days after the allograft, one of them with a limited form of
GVHD, transfusion-free and with normal peripheral blood
counts. One of the two patients (number 17) with Diamond-
Blackfan anemia failed to engraft but is alive 88 days after the
transplant, and the other is alive, chimerised at 121 days after
the graft. The patient with homozygous beta thalassemia is
alive 1038 days after the graft, transfusion-free and fully
chimerised; she got married after her condition turned into
heterozygous beta thalassemia, as her HLA-identical sibling
donor was heterozygous for the disease.
DISCUSSION
In recent years we have been interested in changes to the
therapeutic approaches for hematologic diseases that may result
in both simpliﬁcation and reduction of costs, especially in stem
cell transplants. In a pilot study we have shown that allogeneic
stem cell transplantation can be performed safely on an outpa-
tient basis, if low-intensity regimens are used [8,9]. This initial
encouraging experience has been extended to a larger group of
patients, including children and adolescents. With the available
protocols for children with malignant and nonmalignant blood
diseases, intensive pretransplantation conditioning appears to be
a prerequisite for reliable engraftment; however, this was not the
case in this group of children. RIST using our regimen was well
tolerated, the duration of cytopenias was brief, and the incidence
of other complications was low. We have shown previously that
peripheral blood stem cell allografting can be conducted fully on
an outpatient basis if reduced-intensity preparative regimens are
chosen [17,19]; in this group of children, we were able to
conduct the allograft fully on an outpatient basis on 11 of 21
cases. It is our policy to conduct all RIST on an outpatient basis;
however, in cases in which socioeconomic problems do not
allow this approach, we admit the patients to the hospital
[17,19]. This approach, together with the other changes that we
have made in the preparative regimens results in diminished
costs of the allografting procedure—we were able to calculate
that the median cost of the allografts using this approach is USD
18 000 [17,19].
RIST may also control neoplastic diseases in advanced
stages, but, despite encouraging results, recurrence of the dis-
ease remains the most important cause for transplant failure
[1-2,10,11]. In our group of patients, 8 of 15 individuals with
advanced malignancy who were followed-up died, mostly chil-
dren with ALL; and, as expected, 5 died as a result of relapse. In
contrast, only 1 patient in the group of 6 cases with nonmalig-
nant diseases died. As a result, the 2-year survival of patients
with nonmalignant diseases was signiﬁcantly higher than that
for children with malignant diseases (83% vs 44%, P.01)
(Figure 1).
Limited nonhematologic and hematologic toxicity and
faster hematopoietic recovery compared with those produced by
standard protocols were observed in almost all cases. It is inter-
esting that we have not seen a single case of cytomegalovirus-
Figure 1. Overall survival of 21 children given reduced-intensity allo-
geneic stem cell allografts. The thick line refers to children with non-
malignant conditions, whereas the thin line depicts the survival of
children with malignant diseases.
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related death or disease [20]. Because children who receive
transplants are surviving longer, late effects are becoming more
apparent: thyroid abnormalities, gonadal failure, and growth
hormone deﬁciency are some of the more frequent late effects
observed in childhood after the transplant process, particularly
in children receiving total body irradiation–containing regi-
mens. Additional complications are well documented, including
neurologic, pulmonary, dental, cardiac, opthalmologic, and skel-
etal sequelae [2-5,7]. Furthermore, the risk of secondary malig-
nant diseases, especially for patients prepared with total body
irradiation–containing regimens, is particularly relevant because
the immune system may be impaired for many years after trans-
plantation. It remains to be shown if these late effects of al-
lografting are lesser when using RIST.
The incidence of acute GVHD and its severity appears to
be similar between RIST and standard allografting proce-
dures. However, it is notable that its onset is comparatively
delayed after RIST and often occurs after full recovery from
conditioning toxicity; this deﬁnitely contributes to mitigating
the severity of GVHD-related tissue damage. In many pa-
tients with nonmalignant diseases, this potentially curative
approach of allogeneic transplant is not undertaken because
of unacceptable high transplant-related mortality; however,
RIST represents a promising therapeutic alternative. The
present report includes 6 patients with nonmalignant dis-
eases; all but 1 remained alive, and 1 had a limited chronic
GVHD. Concerning the control of the underlying disease in
the patients with leukemia, these results should be reviewed
carefully against the background of the advanced stage of the
disease and the relatively short follow-up period of the pa-
tients described here.
RIST is much better tolerated and leads to lower toxicity
than conventional chemotherapy or allografting, thus offer-
ing patients the prospect of improvement in both quality of
life and cost-effectiveness. This strategy may be considered
safe enough to be carried out in some circumstances in an
outpatient setting, with evident reduction of transplant-re-
lated costs [17,19]. This is critical in developing countries
where very few individuals can have access to sophisticated
treatments such as conventional bone marrow transplanta-
tion, and this is the main reason for our adapting the condi-
tioning regimens and choosing the more accessible drugs and
methods to conduct RIST [17,19].
In summary, we have demonstrated that RIST in children
permits rapid engraftment from siblings with little toxicity, even
in the presence of advanced disease. This may represent the
treatment of choice for patients who are ineligible for conven-
tional stem cell allografts and may even replace conventional
allografting. Long-term follow-up is needed before this ap-
proach can be extended to patients with more favorable condi-
tions. As other authors have asked, we wonder whether “it is
time to reduce toxicity by reduced intensity conditioning for
allogeneic stem cell transplantation in children” [21].
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